Steigerwald Gordon & Koch Inc. Increases Stake in McKesson Co. (NYSE:MCK)

Steigerwald Gordon & Koch Inc. lifted its holdings in shares of McKesson Co. (NYSE:MCK - Free Report) by 4.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,460 shares of the company's stock after purchasing an additional 1,452 shares during the quarter. McKesson accounts for approximately 2.4% of Steigerwald Gordon & Koch Inc.'s portfolio, making the stock its 17th largest position. Steigerwald Gordon & Koch Inc.'s holdings in McKesson were worth $21,349,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Old North State Trust LLC lifted its stake in McKesson by 1.6% during the third quarter. Old North State Trust LLC now owns 1,138 shares of the company's stock worth $563,000 after purchasing an additional 18 shares during the last quarter. Trust Co. of Vermont raised its holdings in shares of McKesson by 4.8% during the 4th quarter. Trust Co. of Vermont now owns 393 shares of the company's stock valued at $224,000 after buying an additional 18 shares in the last quarter. Black Diamond Financial LLC lifted its position in McKesson by 1.3% in the 3rd quarter. Black Diamond Financial LLC now owns 1,525 shares of the company's stock worth $754,000 after buying an additional 19 shares during the last quarter. QV Investors Inc. boosted its stake in McKesson by 0.6% in the third quarter. QV Investors Inc. now owns 3,499 shares of the company's stock worth $1,730,000 after buying an additional 20 shares in the last quarter. Finally, ASB Consultores LLC grew its position in McKesson by 2.4% during the third quarter. ASB Consultores LLC now owns 879 shares of the company's stock valued at $435,000 after acquiring an additional 21 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Down 0.4 %

Shares of NYSE:MCK traded down $2.50 on Monday, hitting $592.69. The company had a trading volume of 686,346 shares, compared to its average volume of 622,630. The firm's 50-day simple moving average is $595.11 and its two-hundred day simple moving average is $561.01. The firm has a market capitalization of $75.24 billion, a price-to-earnings ratio of 30.69, a P/E/G ratio of 1.26 and a beta of 0.52. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping the consensus estimate of $6.88 by $0.19. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The business had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. During the same period last year, the business posted $6.23 earnings per share. McKesson's quarterly revenue was up 21.3% compared to the same quarter last year. Equities research analysts anticipate that McKesson Co. will post 32.73 EPS for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Monday, December 2nd were paid a $0.71 dividend. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $2.84 annualized dividend and a yield of 0.48%. McKesson's payout ratio is 14.71%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MCK shares. Mizuho initiated coverage on shares of McKesson in a report on Wednesday, December 4th. They issued a "neutral" rating and a $630.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered their price target on shares of McKesson from $623.00 to $579.00 and set a "buy" rating for the company in a research note on Wednesday, September 25th. Wells Fargo & Company raised their price objective on McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a research note on Friday, December 13th. Robert W. Baird raised McKesson from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Finally, Bank of America reduced their price target on McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $646.14.

Insiders Place Their Bets

In other McKesson news, EVP Leann B. Smith sold 579 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now owns 864 shares in the company, valued at approximately $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.11% of the stock is owned by corporate insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.